By Maureen Marino Earlier this week, the HHS doubled down on new vaccine technology. The government granted Maryland-based Novavax a contract worth up to $179.1 million, while Cranbury, NJ’s VaxInnate picked up a potential $196 million deal. Both companies are developing new approaches to seasonal and pandemic influenza that could help the country move away from slower, […]